Plain-English translation of NCT06189170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers studied , an experimental medication, to see if it could be a safe and effective treatment option for Parkinson's disease. The trial tested different doses of this medication in healthy volunteers first, then in people with Parkinson's disease. The main goal was to understand how safe the treatment was and how the body absorbed, distributed, and eliminated it.
Parkinson's disease affects millions of people worldwide, and researchers are constantly searching for new treatments that may help manage symptoms or slow disease progression. This trial was designed to evaluate whether this medication could offer a new option for patients, starting with the foundational safety work needed before larger studies could begin.
Participants received either a single dose or multiple doses of the medication (or placebo) at different strength levels, depending on which group they joined. Healthy volunteers started first with single doses to establish basic safety information, followed by groups receiving multiple doses over time. Throughout the study, participants visited the clinic regularly for blood tests, heart monitoring, physical exams, and other safety checks to track how their bodies responded to the treatment.
AI-generated summary from trial data · Aug 16, 2026 · Not medical advice
United Kingdom
Phase
Safety & dosing
Sponsor
Kariya Pharmaceuticals
Enrollment target
~88 participants
Started
August 2024
Primary completion
June 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2026.